EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$9.38 USD
+0.09 (0.97%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
EYEPOINT PHARMACEUTICALS, INC. [EYPT]
Reports for Purchase
Showing records 21 - 40 ( 83 total )
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Phase 2 Wet AMD Trial Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Positive 12-Month Safety and Efficacy Data in Phase 1 Wet AMD Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Positive Eight-Month Data from Wet AMD Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Angio 2022: Keeping Safety First While Advancing Towards Extended Duration
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Positive Interim Six-Month Data in Wet AMD; Reiterate Buy; Raising PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
3Q21 Financial Results; EYP-1901 Data Update Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
EYP-1901 Demonstrates Positive Three-Month Safety Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat for 2Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYCU Pass-Through Payment Status Extended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYCU Phase 3 Trial Authorized to Start in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
EYP-1901 Shows Encouraging Preliminary Safety Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYXU Procedure Secures Category III CPT Code; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Phase 1 Wet AMD Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
1Q21 Financial Results Roughly In-Line; Reiterate Buy; Adjusting PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Recovering Customer Demand; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
EYP-1901 Phase 1 Wet AMD Trial Initiates Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y